English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The role of a pharmacist in primary health care settings of Pakistan is still obscure. Thus, we aimed to demonstrate the pharmacist-led improvements in glycemic, blood pressure and lipid controls in type 2 diabetes mellitus (T2DM) patients of Lahore, Pakistan.    Methods  The first open label, randomized control trial conducted at a primary health care facility of Lahore, Pakistan by enrolling 244 uncontrolled type 2 diabetes (hemoglobin A1 c, (HbA1c); 10.85 ± 1.74) patients. The pharmacological intervention included identification of drug related problems, drug interactions, change in dose, frequency and therapy switches in collaboration with physician, while non-pharmacological intervention consisted of diet, lifestyle and behavior counseling. Outcome measures were glycemic (HbA1c), blood pressure and lipid controls.    Results  In intra-group comparison, compared to control arm ( C ,  n  = 52), subjects in the intervention arm ( I ,  n  = 83) demonstrated significant differences in process outcome measures; baseline vs final, such as HbA1c ( C ; 10.3 ± 1.3 vs 9.7 ± 1.3,  p  <  0.001,  I ; 10.9 ± 1.7 vs 7.7 ± 0.9,  p  <  0.0001), systolic blood pressure (SBP) ( C ; 129.9 ± 13.9 vs 136 ± 7.1,  p  = 0.0001,  I ; 145 ± 20.4 vs 123.9 ± 9.9 mmHg,  p  <  0.0001), diastolic blood pressure (DBP) ( C ; + 4,  p  = 0.03,  I ; − 7 mmHg,  p  <  0.0001), cholesterol ( C ; 235.8 ± 57.7 vs 220.9 ± 53.2,  p  = 0.15,  I ; 224 ± 55.2 vs 153 ± 25.9 mg/dL,  p  < 0.0001), triglycerides ( C ; 213.2 ± 86.6 vs 172.4 ± 48.7,  p  = 0.001,  I ; 273 ± 119.4 vs 143 ± 31.6 mg/dL,  p  < 0.0001) and estimated glomerular filtration rate (eGFR) ( C ; 77.5 ± 18.6 vs 76 ± 14.2,  p  = 0.5,  I ; 69.4 ± 21.3 vs 93.8 ± 15.2 ml/min/1.73m 2 ,  p  < 0.0001). Likewise, inter-group improvements were more significant in the subjects of intervention group at final follow up in comparison to control for various process outcome measures; HbA1c ( p  < 0.001), SBP ( p  < 0.0001), DBP ( p  = 0.02), cholesterol ( p  < 0.0001), triglycerides ( p  < 0.0001), SCr ( p  < 0.001), eGFR ( p  < 0.001). Moreover, both male and female subjects exhibited similar responses towards intervention with similar improvements in outcome measures.    Conclusion  These data suggested that pharmacist intervention in collaboration with physician in primary health care settings may result in significant improvements in glycemic, blood pressure and lipid controls in Pakistani population.    Trial registration  The trial was registered retrospectively with International Standard Registered Clinical/soCial sTudy Number (ISRCTN) registry on July 26, 2017 under nutritional, metabolic, endocrine category with assigned registration #  ISRCTN22657497  and can be assessed at 10.1186/ISRCTN22657497    Electronic supplementary material  The online version of this article (10.1186/s12913-019-4274-z) contains supplementary material, which is available to authorized users.

A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan